Survival after recurrence in early-stage cervical cancer
patients

a 2021

Survival after recurrence in early-stage cervical cancer patients

LONKHUIJZEN, L Van, L DOSTALEK, Jiří JARKOVSKÝ, LOPEZ, H FALCONER et. al.

Základní údaje

Originální název

Survival after recurrence in early-stage cervical cancer patients

Autoři

Vydání

ESGO 2021 Congress, 2021

Další údaje

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.661

Organizační jednotka

Lékařská fakulta

ISSN

Změněno: 28. 1. 2022 08:14, Mgr. Tereza Miškechová

Anotace

V originále

Introduction/Background*Up to 26% of early-stage cervical cancer patients relapse after primary surgical treatment. However, little is known about the factors affecting prognosis following disease recurrence. Hence, the aim of this study was to evaluate post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors. Methodology Data from 528 early-stage cervical cancer patients who relapsed after primary surgical treatment performed between 2007 and 2016 were obtained from the SCCAN study (Surveillance in Cervical CANcer). Parameters related both to primary disease and recurrence diagnosis were combined to develop a multivariable Cox proportional hazards model predicting PR-DSS. Result(s)*Five-year PR-DSS reached 39.1% (95% confidence interval: 22.7% – 44.5%) with median disease-free survival between primary surgery and recurrence diagnosis (DFI1) of 1.5 years and median survival after recurrence of 2.5 years. Six variables significant in multivariable analysis were included in the PR-DSS prognostic model; two related to the primary disease characteristics: maximal diameter of the tumour and lymphovascular space invasion; and four related to the recurrence diagnosis: DFI1, age, presence of symptoms, and recurrence localization (table 1). C-statistics of the final model after 10-fold internal validation equalled 0.701 (95% CI: 0.675 – 0.727). Five risk groups significantly differing in prognosis were identified, with 5-year DSS after recurrence of 85.6%, 62.0%, 46.7, 19.7%, and 0% in the highest risk group (figure 1).

Citovat

LONKHUIJZEN, L Van, L DOSTALEK, Jiří JARKOVSKÝ, LOPEZ, H FALCONER, G SCAMBIA, AYHAN, S KIM, D Isla ORTIZ, J KLAT, OBERMAIR, GDI MARTINO, R PAREJA, R MANCHANDA, J KOSTUN, R Dos REIS, I ZAPARDIEL, Vít WEINBERGER a D CIBULA. Survival after recurrence in early-stage cervical cancer patients. In ESGO 2021 Congress. 2021. ISSN 1048-891X.

@proceedings{1828138,
   author = {Lonkhuijzen, L Van and Dostalek, L and Jarkovský, Jiří and Lopez, and Falconer, H and Scambia, G and Ayhan, and Kim, S and Ortiz, D Isla and Klat, J and Obermair, and Martino, GDI and Pareja, R and Manchanda, R and Kostun, J and Reis, R Dos and Zapardiel, I and Weinberger, Vít and Cibula, D},
   booktitle = {ESGO 2021 Congress},
   title = {Survival after recurrence in early-stage cervical cancer patients},
   year = {2021}
}

TY  - CONF
ID  - 1828138
AU  - Lonkhuijzen, L Van - Dostalek, L - Jarkovský, Jiří - Lopez,
AU  - Falconer, H - Scambia, G - Ayhan,
AU  - Kim, S - Ortiz, D Isla - Klat, J - Obermair,
AU  - Martino, GDI - Pareja, R - Manchanda, R - Kostun, J - Reis, R Dos - Zapardiel, I - Weinberger, Vít - Cibula, D
PY  - 2021
TI  - Survival after recurrence in early-stage cervical cancer patients
N2  - Introduction/Background*Up to 26% of early-stage cervical cancer patients relapse after primary surgical treatment. However, little is known about the factors affecting prognosis following disease recurrence. Hence, the aim of this study was to evaluate post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors. Methodology Data from 528 early-stage cervical cancer patients who relapsed after primary surgical treatment performed between 2007 and 2016 were obtained from the SCCAN study (Surveillance in Cervical CANcer). Parameters related both to primary disease and recurrence diagnosis were combined to develop a multivariable Cox proportional hazards model predicting PR-DSS. Result(s)*Five-year PR-DSS reached 39.1% (95% confidence interval: 22.7% – 44.5%) with median disease-free survival between primary surgery and recurrence diagnosis (DFI1) of 1.5 years and median survival after recurrence of 2.5 years. Six variables significant in multivariable analysis were included in the PR-DSS prognostic model; two related to the primary disease characteristics: maximal diameter of the tumour and lymphovascular space invasion; and four related to the recurrence diagnosis: DFI1, age, presence of symptoms, and recurrence localization (table 1). C-statistics of the final model after 10-fold internal validation equalled 0.701 (95% CI: 0.675 – 0.727). Five risk groups significantly differing in prognosis were identified, with 5-year DSS after recurrence of 85.6%, 62.0%, 46.7, 19.7%, and 0% in the highest risk group (figure 1).
ER  -

Podrobný výpis o publikaci